liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk.
Asklepios Clinic St Georg, Hamburg, Germany .
Assmann-Foundation for Prevention, Münster, Germany.
University, Valencia, Spain .
Faculty of Medicine at the Université de Montréal, Canada.
Show others and affiliations
2016 (English)In: European Journal of Preventive Cardiology, ISSN 2047-4873, E-ISSN 2047-4881, Vol. 23, no 3, 275-281 p.Article in journal (Refereed) Published
Abstract [en]

Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy.

Place, publisher, year, edition, pages
2016. Vol. 23, no 3, 275-281 p.
Keyword [en]
Hypercholesterolaemia; cardiovascular prevention
National Category
Cardiac and Cardiovascular Systems
Identifiers
URN: urn:nbn:se:liu:diva-124057DOI: 10.1177/2047487314567001ISI: 000369526800006PubMedID: 25595550OAI: oai:DiVA.org:liu-124057DiVA: diva2:895593
Note

Funding agencies:DMW: personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Merck Sharpe and Dohme, Novartis, Roche, Sanofi, Bayer, Janssen-Cilag, Lilly, NovoNordisk; non-financial support from Sanofi Germany, outside the submitted work. GA, RC, JD, EF, HG, AGO, WFR, ES: none. AVE: personal fees from Amgen Switzerland, Astra Zeneca Switzerland, Merck Sharpe and Dohme Switzerland, Sanofi Aventis, outside the submitted work; and member of the Executive Board of the European Atherosclerosis Society as well as the president of the Swiss Working Group on Lipids and Atherosclerosis (= Swiss Atherosclerosis Society), which both published own recommendations for the prevention of heart disease by lipid-lowering therapy.

Available from: 2016-01-19 Created: 2016-01-19 Last updated: 2017-04-21

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Olsson, Anders G
By organisation
Department of EndocrinologyDivision of Cardiovascular MedicineFaculty of Medicine and Health Sciences
In the same journal
European Journal of Preventive Cardiology
Cardiac and Cardiovascular Systems

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 114 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf